维得利珠单抗对比阿达木单抗治疗溃疡性结肠炎的组织学结局:VARSITY研究结果
VARSITY研究显示,溃疡性结肠炎患者接受维得利珠单抗静脉300mg每8周或阿达木单抗皮下40mg每2周维持治疗后,维得利珠单抗在第14周和第52周的組織学缓解率、最小组织学疾病活动度率及黏膜愈合率均显著高于阿达木单抗,且在抗TNF初治和经治失败亚组中结果一致。
要点
- 维得利珠单抗第52周组织学缓解率(Geboes<2)为29.2%,阿达木单抗为8.3%。
- 维得利珠单抗第14周组织学缓解率(Geboes<2)为16.7%,阿达木单抗为7.3%。
- 抗TNF初治患者组织学结局一般优于经治失败患者。
核心结论
- 在溃疡性结肠炎中,维得利珠单抗的组织学缓解、最小组织学疾病活动度及组织学联合内镜结局均优于阿达木单抗。
- 组织学获益在抗TNF初治和经治失败亚组中均一致。
研究设计与样本
- VARSITY为随机1:1对照研究,患者接受维得利珠单抗静脉300mg每8周(n=383)或阿达木单抗皮下40mg每2周(n=386)维持治疗,均按标准诱导。
- 共769例患者接受治疗,使用Geboes指数和Robarts组织病理学指数(RHI)评估第14周和第52周的组织学探索性终点。
主要发现
- 第52周组织学缓解:Geboes<2为29.2% vs 8.3%(Δ20.9%,95%CI 15.6%-26.2%,P<.0001);RHI≤2为37.6% vs 19.9%(Δ17.6%,95%CI 11.3%-23.8%,P<.0001)。
- 第52周黏膜愈合(组织学联合内镜改善)率:Geboes为25.6% vs 6.7%;RHI为30.5% vs 14.5%。
- 最小组织学疾病活动度结果与组织学缓解相似。
- 抗TNF初治患者组织学结局一般优于经治失败患者。
关键数值与推荐
- 组织学缓解定义为Geboes<2或RHI≤2。
- 最小组织学疾病活动度定义为Geboes≤3.1或RHI≤4。
临床怎么用
- 对于溃疡性结肠炎,维得利珠单抗在组织学缓解方面优于阿达木单抗,可支持临床决策时考虑组织学获益。
- 抗TNF初治患者组织学结局更好,提示早期使用维得利珠单抗可能更有利。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes. METHODS: Patients in VARSITY were randomized 1:1 to maintenance with vedolizumab IV 300 mg every 8 weeks or adalimumab SC 40 mg every 2 weeks (both following standard induction). Geboes Index and Robarts Histopathology Index (RHI) scores were used to assess prespecified histologic exploratory end points of histologic remission (Geboes <2 or RHI ≤2) and minimal histologic disease activity (Geboes ≤3.1 or RHI ≤4) at weeks 14 and 52. RESULTS: In total, 769 patients received vedolizumab (n = 383) or adalimumab (n = 386). Mean baseline histologic disease activity was similar between vedolizumab and adalimumab groups. Vedolizumab induced greater histologic remission than adalimumab at week 14 (Geboes: 16.7% vs 7.3%, Δ9.4% [95% confidence interval {CI}, 4.9%-13.9%], P < .0001; RHI: 25.6% vs 16.1%, Δ9.5% [95% CI, 3.8%-15.2%], P = .0011) and week 52 (Geboes: 29.2% vs 8.3%, Δ20.9% [95% CI, 15.6%-26.2%], P < .0001; RHI: 37.6% vs 19.9%, Δ17.6% [95% CI, 11.3%-23.8%], P < .0001) overall and in both anti-tumor necrosis factor (TNF)-naïve and -failure subgroups. Results were similar for minimal histologic disease activity. Histologic outcomes were generally better in anti-TNF-naïve vs -failure patients. At week 52, rates of mucosal healing (composite end point of histologic plus endoscopic improvement) were also higher with vedolizumab than adalimumab (Geboes: 25.6% vs 6.7%; RHI: 30.5% vs 14.5%). CONCLUSIONS: Higher rates of histologic remission, minimal histologic disease activity, and combined histologic plus endoscopic outcomes were observed with vedolizumab than with adalimumab in ulcerative colitis in both anti-TNF-naïve and -failure subgroups. REGISTRATION: ClinicalTrials.gov NCT02497469; EudraCT 2015-000939-33.
引用
- Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 2021. PMID: 34144047. doi:10.1053/j.gastro.2021.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。